Executive Summary: Key Legal and Evidentiary Issues

• Biosenta Inc. defaulted on a $6.5 million promissory note, with total indebtedness reaching approximately $7,129,388.79 as of February 23, 2026.
• Central to the dispute is whether the Applicant's security interest extended beyond a specific U.S. patent and related Tri-Filler inventory to cover all of Biosenta's assets and undertaking.
• No binding extension agreement or promissory estoppel was established, as the alleged oral agreement lacked essential terms and Biosenta failed to show detrimental reliance.
• A key distinction arose between a privately appointed receiver — whose authority derives from the parties' security agreement — and a court-appointed receiver, whose authority derives from statute and court order.
• The Applicant failed to adduce sufficient evidence to justify a court-appointed receivership over Biosenta's entire business, including evidence on the realizable value of the secured collateral.
• Biosenta's insolvency on a cash-flow basis was clear from its own financial disclosures, but this alone did not satisfy the "just and convenient" standard required for a court-appointed receiver.

Facts of the case

1943391 Ontario Ltd. (the Applicant) and Biosenta Inc. (the Respondent) entered into a joint venture agreement in 2017, under which the Applicant provided funding to Biosenta for product development. Biosenta is a public company listed on the Canadian Securities Exchange and is engaged in developing patented antimicrobial technology called Tri-Filler, which is designed to eliminate harmful pathogens and reduce microbial growth and infection when added to other products. Over time, the joint venture terms were amended, and in 2020, Biosenta agreed to repay funds borrowed from the Applicant. In May 2021, Biosenta granted the Applicant a security interest to secure its repayment obligations.

In June 2023, the parties agreed to terminate the joint venture. As part of the termination terms, Biosenta agreed to issue the Applicant 3 million common shares at an implicit subscription price of $1.2 million (40 cents per share) and to pay $6.5 million under a promissory note. The promissory note provided that the debt would become due in full on December 31, 2025, with interest accruing at CIBC's prime rate plus 3% commencing 120 days after execution, payable quarterly. In July 2023, the parties also agreed to amend the Applicant's security agreement to secure obligations under the promissory note rather than the terminated joint venture agreement.

Biosenta failed to repay the debt when it matured on December 31, 2025. Biosenta's President and CEO, Mr. Gill, claimed he had reached an informal agreement with Mr. Connor, President of the Applicant, at a lunch meeting on July 5, 2025, for an extension of the note's maturity date. The Applicant formally requested a written extension proposal from Biosenta by November 30, 2025, and Biosenta responded with a 20-page Commercialization Plan requesting a three-year extension. On December 13, 2025, the Applicant notified Biosenta that it did not agree to any extension and expected payment as agreed. Biosenta did not repay the debt on the due date or at any time thereafter. On February 23, 2026, the Applicant formally demanded repayment, citing total indebtedness of $7,129,388.79 plus $25,000 and HST for legal fees as of that date, and delivered a notice under s. 244 of the Bankruptcy and Insolvency Act.

Policy terms and contractual clauses at issue

The security agreement granted the Applicant a security interest in U.S. Patent No. 9,493,658, entitled Method and Apparatus for the Preparation of Calcium Carbonate Coated Calcium Hydroxide Particles, and in Tri-Filler and the proceeds of both. Articles 4.1 and 4.2 of the security agreement prohibited Biosenta from encumbering, selling, licensing, or otherwise disposing of the collateral. Article 5.2 authorized the Applicant to appoint a receiver to take possession of and sell the collateral upon default, with the privately appointed receiver functioning as agent of the secured creditor.

Article 4.6 of the joint venture termination agreement qualified the Applicant's security interest by providing that the Applicant must release its security if Biosenta reasonably determines that a release is required to enter into a commercialization license with a third party, or once at least $3,000,000 of the promissory note is repaid. This clause was central to the court's assessment of the scope and durability of the Applicant's security.

Reasoning and analysis

Justice Myers identified a fundamental distinction between a privately appointed receiver — which takes its authority from the security agreement and acts as the creditor's agent — and a court-appointed receiver, which takes its authority from statute (such as s. 101 of the Courts of Justice Act or s. 243 of the Bankruptcy and Insolvency Act), acts as a neutral officer of the court, and does not take instructions from the appointing creditor. The court emphasized that a contractual right to appoint a receiver privately does not translate into a contractual right to a court appointment, nor does it make a court appointment automatic or presumptively appropriate.

Applying the "just and convenient" standard, the court found the Applicant's evidentiary record critically deficient. The Applicant had not adduced evidence on the realizable value of the secured collateral — the U.S. patent and any Tri-Filler inventory — or on whether a private receivership would be inadequate. The Applicant's security was limited to one patent, whereas counsel submitted (without sworn evidence) that Biosenta may hold two additional U.S. patents providing alternative methods of producing Tri-Filler. The court was therefore unable to assess whether the secured patent remained in active use, whether its value depended on the business continuing as a going concern, or whether a full receivership over Biosenta's entire undertaking was warranted or would cause harm.

On the question of the alleged extension agreement, the court accepted the concession of Biosenta's own counsel that no binding extension had been reached and that promissory estoppel did not apply. The oral discussions in July 2025 lacked essential terms, and Biosenta had not demonstrated any detrimental reliance on any representation made by the Applicant. The court also noted that the Applicant's s. 244 BIA notice incorrectly described the secured collateral as all assets at Biosenta's address, when in fact the security was confined to the specified patent and related inventory — an error the Applicant subsequently corrected by issuing a PPSA notice properly defining the collateral.

The court further found that the Applicant's assertion of lost confidence in Biosenta's management was unsupported: the Applicant had taken no meaningful enforcement steps for nearly five months after default, which was inconsistent with a creditor genuinely distrustful of management. The court distinguished the present case from Canadian Equipment Finance and Leasing Inc. v. The Hypoint Company Limited, 2022 ONSC 6186, where a court-appointed receivership over the full business was justified because competing creditors threatened asset dissipation in a company that had already shut down — circumstances entirely absent here.

Ruling and overall outcome

Justice Myers dismissed the application. The court held that on the evidence presented, it was not satisfied that it was just or convenient to appoint a court-appointed receiver over Biosenta's assets, property, and undertaking as sought. The evidentiary record was insufficient to determine what benefit a receivership would bring, at what cost, and to whom. The court noted that nothing precluded the Applicant from enforcing its debt in the ordinary course or from returning to court on a more complete evidentiary record, including input from intellectual property and industry experts. Costs submissions were ordered to be exchanged between the parties, with Biosenta to deliver its submissions by June 1, 2026, and the Applicant by June 8, 2026. The Applicant, 1943391 Ontario Ltd., was the unsuccessful party; no monetary awar